An Open-Label Trial of Riluzole in Patients With Treatment-Resistant Major Depression
摘要：
This study was conducted to determine the efficacy and safety of riluzole, a glutamate-modulating agent, in patients with recurrent major depression.After a 1-week drug-free period, subjects 18 years or older with a diagnosis of recurrent major depression and a Montgomery-Asberg Depression Rating Scale score > or = 20 received riluzole monotherapy (100-200 mg/day) openly for 6 weeks.Nineteen treatment-resistant depressed patients, 53% of whom were classified as having stage 2 treatment resistance or greater, received riluzole at a mean dose of 169 mg/day. Significant improvement occurred during weeks 3 through 6 for all patients and weeks 2 through 6 for completers.Although preliminary, these results indicate that riluzole may have antidepressant properties in some patients.
展开
关键词：
Humans Recurrence Riluzole Anticonvulsants Severity of Illness Index Questionnaires Adolescent Adult Aged Middle Aged
DOI：
10.1176/appi.ajp.161.1.171
被引量：
年份：
2004
Semantic Scholar
万方医学
dx.doi.org
NCBI
Europe PMC
查看更多
Oxford Univ Press
NCBI
EureKaMag.com
ResearchGate
EureKaMag.com
(全网免费下载)
ResearchGate
(全网免费下载)
ProQuest
scienceopen.com
fasebj.org
psychiatryonline.org
(全网免费下载)
pubfacts.com
cmaj.ca
readcube.com
mcponline.org
biologicalpsychiatryjournal.com
ajp.psychiatryonline.org
(全网免费下载)
onAcademic
psychiatryonline.org
psychiatryonline.org
(全网免费下载)
mendeley.com
EureKaMag.com
(全网免费下载)
ResearchGate
(全网免费下载)
ajp.psychiatryonline.org
(全网免费下载)
psychiatryonline.org
(全网免费下载)
psychiatryonline.org
(全网免费下载)
通过文献互助平台发起求助，成功后即可免费获取论文全文。
相似文献
参考文献
引证文献
辅助模式
引用
文献可以批量引用啦~
欢迎点我试用！
